» Articles » PMID: 33755854

Current Treatment Options and Challenges in Patients with Type 1 Diabetes: Pharmacological, Technical Advances and Future Perspectives

Overview
Publisher Springer
Specialty Endocrinology
Date 2021 Mar 23
PMID 33755854
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 diabetes mellitus imposes a significant burden of complications and mortality, despite important advances in treatment: subjects affected by this disease have also a worse quality of life-related to disease management. To overcome these challenges, different new approaches have been proposed, such as new insulin formulations or innovative devices. The introduction of insulin pumps allows a more physiological insulin administration with a reduction of HbA1c level and hypoglycemic risk. New continuous glucose monitoring systems with better accuracy have allowed, not only better glucose control, but also the improvement of the quality of life. Integration of these devices with control algorithms brought to the creation of the first artificial pancreas, able to independently gain metabolic control without the risk of hypo- and hyperglycemic crisis. This approach has revolutionized the management of diabetes both in terms of quality of life and glucose control. However, complete independence from exogenous insulin will be obtained only by biological approaches that foresee the replacement of functional beta cells obtained from stem cells: this will be a major challenge but the biggest hope for the subjects with type 1 diabetes. In this review, we will outline the current scenario of innovative diabetes management both from a technological and biological point of view, and we will also forecast some cutting-edge approaches to reduce the challenges that hamper the definitive cure of diabetes.

Citing Articles

Could hypoxic conditioning augment the potential of mesenchymal stromal cell-derived extracellular vesicles as a treatment for type 1 diabetes?.

Forkan C, Shrestha A, Yu A, Chuang C, Pociot F, Yarani R Stem Cell Res Ther. 2025; 16(1):37.

PMID: 39901225 PMC: 11792614. DOI: 10.1186/s13287-025-04153-4.


Current Challenges in Pancreas and Islet Transplantation: A Scoping Review.

Altabas V, Bulum T Biomedicines. 2025; 12(12).

PMID: 39767759 PMC: 11673013. DOI: 10.3390/biomedicines12122853.


The N-Methyl-D-Aspartate Receptor Antagonist Dextromethorphan Improves Glucose Homeostasis and Preserves Pancreatic Islets in NOD Mice.

Wormeyer L, Nortmann O, Hamacher A, Uhlemeyer C, Belgardt B, Eberhard D Horm Metab Res. 2024; 56(3):223-234.

PMID: 38168730 PMC: 10901624. DOI: 10.1055/a-2236-8625.


Chimeric Antigen Receptor (CAR)-Based Cell Therapy for Type 1 Diabetes Mellitus (T1DM); Current Progress and Future Approaches.

Mohammadi V, Jahani Maleki A, Nazari M, Siahmansouri A, Moradi A, Elahi R Stem Cell Rev Rep. 2023; 20(3):585-600.

PMID: 38153634 DOI: 10.1007/s12015-023-10668-1.


Dietary treatment of type 1 diabetes - once upon a time versus today.

Soczewka M, Kedzia A, Skowronska B, Niechcial E Pediatr Endocrinol Diabetes Metab. 2023; 29(3):184-189.

PMID: 38031833 PMC: 10679909. DOI: 10.5114/pedm.2023.132027.


References
1.
Cryer P, Davis S, Shamoon H . Hypoglycemia in diabetes. Diabetes Care. 2003; 26(6):1902-12. DOI: 10.2337/diacare.26.6.1902. View

2.
Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

3.
Gruessner R, Gruessner A . The current state of pancreas transplantation. Nat Rev Endocrinol. 2013; 9(9):555-62. DOI: 10.1038/nrendo.2013.138. View

4.
DAmour K, Bang A, Eliazer S, Kelly O, Agulnick A, Smart N . Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006; 24(11):1392-401. DOI: 10.1038/nbt1259. View

5.
Breton M, Brown S, Karvetski C, Kollar L, Topchyan K, Anderson S . Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. Diabetes Technol Ther. 2014; 16(8):506-11. PMC: 4116126. DOI: 10.1089/dia.2013.0333. View